 Peter Mourani
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 329 | 5.010 |
Why?
| | Intensive Care Units, Pediatric | 26 | 2023 | 147 | 2.870 |
Why?
| | Cardiopulmonary Resuscitation | 14 | 2023 | 222 | 2.390 |
Why?
| | Heart Arrest | 15 | 2023 | 292 | 2.360 |
Why?
| | Respiration, Artificial | 17 | 2023 | 529 | 2.140 |
Why?
| | Critical Illness | 23 | 2024 | 644 | 2.070 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1727 | 2.040 |
Why?
| | Infant, Premature | 17 | 2021 | 476 | 2.030 |
Why?
| | Pneumonia, Ventilator-Associated | 3 | 2021 | 40 | 1.920 |
Why?
| | Microbiota | 8 | 2024 | 647 | 1.850 |
Why?
| | Shock, Septic | 11 | 2023 | 186 | 1.800 |
Why?
| | Sepsis | 12 | 2023 | 509 | 1.490 |
Why?
| | Child | 86 | 2024 | 18404 | 1.360 |
Why?
| | Trachea | 3 | 2017 | 224 | 1.340 |
Why?
| | Respiratory Insufficiency | 5 | 2021 | 290 | 1.340 |
Why?
| | Prospective Studies | 42 | 2024 | 6217 | 1.340 |
Why?
| | Infant, Newborn | 40 | 2024 | 5043 | 1.300 |
Why?
| | Respiratory Tract Infections | 5 | 2024 | 319 | 1.300 |
Why?
| | Vascular Diseases | 5 | 2020 | 230 | 1.120 |
Why?
| | Critical Care | 6 | 2021 | 476 | 1.050 |
Why?
| | Premature Birth | 4 | 2021 | 276 | 1.030 |
Why?
| | Infant | 42 | 2024 | 7959 | 0.960 |
Why?
| | Echocardiography | 7 | 2021 | 553 | 0.920 |
Why?
| | Lung | 9 | 2024 | 3558 | 0.920 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 217 | 0.900 |
Why?
| | Humans | 125 | 2024 | 114623 | 0.880 |
Why?
| | Influenza, Human | 9 | 2023 | 546 | 0.880 |
Why?
| | Child, Preschool | 35 | 2024 | 9108 | 0.870 |
Why?
| | Heart Ventricles | 2 | 2021 | 712 | 0.870 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 32 | 0.860 |
Why?
| | Intensive Care Units | 9 | 2023 | 617 | 0.840 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 485 | 0.800 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 250 | 0.780 |
Why?
| | Intubation, Intratracheal | 3 | 2019 | 216 | 0.770 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 97 | 0.760 |
Why?
| | Quality of Life | 12 | 2024 | 2353 | 0.730 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 217 | 0.690 |
Why?
| | Patient Discharge | 11 | 2024 | 771 | 0.670 |
Why?
| | Aftercare | 5 | 2024 | 186 | 0.640 |
Why?
| | Male | 55 | 2024 | 55554 | 0.600 |
Why?
| | Nutritional Support | 1 | 2017 | 27 | 0.590 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 138 | 0.590 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 91 | 0.580 |
Why?
| | Female | 58 | 2024 | 59466 | 0.580 |
Why?
| | Gestational Age | 7 | 2021 | 759 | 0.570 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.560 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 46 | 0.530 |
Why?
| | Risk Factors | 20 | 2022 | 8628 | 0.530 |
Why?
| | Coinfection | 3 | 2022 | 120 | 0.530 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 9 | 0.500 |
Why?
| | Adolescent | 34 | 2023 | 17831 | 0.500 |
Why?
| | Energy Intake | 1 | 2017 | 427 | 0.490 |
Why?
| | Nitric Oxide | 6 | 2022 | 823 | 0.480 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 15 | 0.460 |
Why?
| | Chlorides | 3 | 2020 | 127 | 0.460 |
Why?
| | Retrospective Studies | 26 | 2023 | 12542 | 0.460 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 10 | 0.450 |
Why?
| | Metapneumovirus | 1 | 2013 | 12 | 0.450 |
Why?
| | Myocardial Contraction | 1 | 2015 | 313 | 0.440 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 94 | 0.440 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 129 | 0.440 |
Why?
| | Bacteria | 4 | 2022 | 725 | 0.430 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 301 | 0.410 |
Why?
| | Energy Metabolism | 1 | 2017 | 731 | 0.410 |
Why?
| | Patient Readmission | 2 | 2018 | 609 | 0.410 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 181 | 0.410 |
Why?
| | Lung Diseases | 2 | 2010 | 701 | 0.410 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 97 | 0.410 |
Why?
| | Oxygen | 3 | 2019 | 854 | 0.400 |
Why?
| | Bacterial Infections | 3 | 2023 | 218 | 0.400 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 467 | 0.390 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 231 | 0.390 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.380 |
Why?
| | Embolectomy | 1 | 2011 | 11 | 0.380 |
Why?
| | Bereavement | 2 | 2021 | 49 | 0.370 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 637 | 0.370 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 358 | 0.370 |
Why?
| | Influenza A virus | 3 | 2020 | 90 | 0.360 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1015 | 0.350 |
Why?
| | Wilms Tumor | 1 | 2011 | 68 | 0.350 |
Why?
| | Milrinone | 2 | 2021 | 24 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1394 | 0.350 |
Why?
| | Vasodilator Agents | 3 | 2021 | 302 | 0.350 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 26 | 0.320 |
Why?
| | Coronary Care Units | 2 | 2018 | 13 | 0.310 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 191 | 0.310 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 82 | 0.310 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 57 | 0.300 |
Why?
| | Sulfones | 1 | 2008 | 97 | 0.300 |
Why?
| | Logistic Models | 6 | 2019 | 1840 | 0.300 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 146 | 0.300 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 67 | 0.290 |
Why?
| | Quality Improvement | 3 | 2022 | 950 | 0.290 |
Why?
| | Cohort Studies | 13 | 2022 | 4894 | 0.290 |
Why?
| | Heart Diseases | 2 | 2023 | 331 | 0.290 |
Why?
| | Administration, Inhalation | 5 | 2022 | 641 | 0.290 |
Why?
| | Health Resources | 4 | 2022 | 122 | 0.290 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 327 | 0.280 |
Why?
| | Research Design | 4 | 2022 | 928 | 0.280 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 241 | 0.280 |
Why?
| | Staphylococcus | 2 | 2017 | 69 | 0.280 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 336 | 0.280 |
Why?
| | Metagenomics | 4 | 2023 | 131 | 0.270 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4411 | 0.270 |
Why?
| | Piperazines | 1 | 2008 | 309 | 0.270 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 186 | 0.260 |
Why?
| | Hospital Mortality | 8 | 2023 | 776 | 0.260 |
Why?
| | Length of Stay | 4 | 2020 | 962 | 0.250 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1477 | 0.250 |
Why?
| | Biomarkers | 8 | 2023 | 3408 | 0.250 |
Why?
| | Pregnancy | 9 | 2022 | 5517 | 0.240 |
Why?
| | Time Factors | 9 | 2020 | 6112 | 0.240 |
Why?
| | Diastole | 3 | 2019 | 130 | 0.230 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 15 | 0.230 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 8 | 0.230 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 36 | 0.230 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 411 | 0.220 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2387 | 0.220 |
Why?
| | Tunica Intima | 1 | 2004 | 78 | 0.220 |
Why?
| | Skin Pigmentation | 1 | 2024 | 39 | 0.220 |
Why?
| | Oximetry | 1 | 2024 | 81 | 0.220 |
Why?
| | Epinephrine | 2 | 2022 | 163 | 0.220 |
Why?
| | Respiration | 1 | 2024 | 179 | 0.210 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.210 |
Why?
| | Age Factors | 6 | 2021 | 2894 | 0.210 |
Why?
| | Treatment Outcome | 11 | 2022 | 9084 | 0.210 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 13 | 0.210 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 201 | 0.210 |
Why?
| | Cotinine | 1 | 2023 | 69 | 0.200 |
Why?
| | Wounds and Injuries | 2 | 2021 | 745 | 0.200 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 11 | 0.200 |
Why?
| | Hypotension | 1 | 2023 | 116 | 0.200 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 235 | 0.200 |
Why?
| | Sodium | 1 | 2022 | 183 | 0.200 |
Why?
| | Protein Kinases | 1 | 2004 | 307 | 0.200 |
Why?
| | Central Venous Catheters | 1 | 2022 | 40 | 0.190 |
Why?
| | Smoke | 1 | 2023 | 123 | 0.190 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 151 | 0.190 |
Why?
| | Parents | 4 | 2021 | 1186 | 0.190 |
Why?
| | United States | 11 | 2022 | 12176 | 0.190 |
Why?
| | Prone Position | 1 | 2021 | 27 | 0.190 |
Why?
| | Central Venous Pressure | 1 | 2021 | 12 | 0.190 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 60 | 0.190 |
Why?
| | Capnography | 1 | 2021 | 11 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1077 | 0.190 |
Why?
| | Patient Positioning | 1 | 2021 | 42 | 0.180 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 121 | 0.180 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 83 | 0.180 |
Why?
| | Pregnancy in Diabetics | 1 | 2022 | 82 | 0.180 |
Why?
| | Common Data Elements | 1 | 2020 | 10 | 0.180 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 47 | 0.180 |
Why?
| | Communicable Diseases | 1 | 2022 | 129 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 15 | 0.180 |
Why?
| | Shock | 1 | 2022 | 83 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3039 | 0.180 |
Why?
| | Thoracic Injuries | 1 | 2021 | 55 | 0.180 |
Why?
| | Iloprost | 1 | 2021 | 46 | 0.180 |
Why?
| | Young Adult | 9 | 2022 | 10455 | 0.180 |
Why?
| | Spinal Injuries | 1 | 2021 | 47 | 0.180 |
Why?
| | Multiple Trauma | 1 | 2021 | 96 | 0.180 |
Why?
| | Vasopressins | 1 | 2021 | 56 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 313 | 0.180 |
Why?
| | Extremities | 1 | 2021 | 113 | 0.180 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 70 | 0.180 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 608 | 0.180 |
Why?
| | Epoprostenol | 1 | 2021 | 133 | 0.170 |
Why?
| | Abdominal Injuries | 1 | 2021 | 108 | 0.170 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 150 | 0.170 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 18 | 0.170 |
Why?
| | Morbidity | 4 | 2022 | 280 | 0.170 |
Why?
| | Caregivers | 3 | 2021 | 717 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1430 | 0.170 |
Why?
| | Medical Audit | 1 | 2020 | 75 | 0.170 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 20 | 0.160 |
Why?
| | Medical Records | 1 | 2020 | 153 | 0.160 |
Why?
| | Nervous System Diseases | 1 | 2022 | 253 | 0.160 |
Why?
| | Medicine | 1 | 2020 | 102 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 414 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2020 | 2762 | 0.160 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 80 | 0.160 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 407 | 0.160 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 78 | 0.160 |
Why?
| | Adult | 10 | 2024 | 30528 | 0.160 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 119 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2084 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 126 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2019 | 155 | 0.150 |
Why?
| | Blood Pressure | 4 | 2023 | 1538 | 0.150 |
Why?
| | Hospitalization | 4 | 2023 | 1749 | 0.150 |
Why?
| | Proteomics | 3 | 2020 | 836 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 281 | 0.150 |
Why?
| | Academic Medical Centers | 2 | 2017 | 410 | 0.150 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 69 | 0.150 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 66 | 0.150 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.150 |
Why?
| | Chorioamnionitis | 1 | 2017 | 36 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 75 | 0.140 |
Why?
| | Motivation | 1 | 2021 | 494 | 0.140 |
Why?
| | Respiratory System | 1 | 2018 | 137 | 0.140 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 287 | 0.140 |
Why?
| | Heart Failure | 2 | 2021 | 1945 | 0.140 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 66 | 0.140 |
Why?
| | Mutation, Missense | 1 | 2019 | 293 | 0.140 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 178 | 0.140 |
Why?
| | Inservice Training | 1 | 2018 | 105 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 470 | 0.140 |
Why?
| | Delirium | 1 | 2018 | 66 | 0.140 |
Why?
| | Dysbiosis | 1 | 2018 | 146 | 0.140 |
Why?
| | Chronic Disease | 3 | 2022 | 1578 | 0.140 |
Why?
| | Pneumonia | 1 | 2022 | 567 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 176 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 439 | 0.130 |
Why?
| | Hemodynamics | 3 | 2023 | 1012 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 411 | 0.130 |
Why?
| | MicroRNAs | 1 | 2022 | 600 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 295 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 101 | 0.130 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 125 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 837 | 0.130 |
Why?
| | Mothers | 2 | 2022 | 651 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2537 | 0.130 |
Why?
| | Needs Assessment | 1 | 2017 | 314 | 0.130 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 18 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2019 | 291 | 0.130 |
Why?
| | Delphi Technique | 3 | 2020 | 160 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 165 | 0.130 |
Why?
| | Computational Biology | 1 | 2019 | 530 | 0.130 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 39 | 0.130 |
Why?
| | Indiana | 1 | 2015 | 26 | 0.120 |
Why?
| | Medical Informatics | 1 | 2016 | 90 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.120 |
Why?
| | Trauma Centers | 3 | 2022 | 362 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 338 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 344 | 0.120 |
Why?
| | Hypertension | 2 | 2019 | 1056 | 0.110 |
Why?
| | Metabolomics | 1 | 2018 | 521 | 0.110 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 10 | 0.110 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 480 | 0.110 |
Why?
| | Birth Weight | 1 | 2017 | 440 | 0.110 |
Why?
| | Schools, Medical | 1 | 2015 | 120 | 0.110 |
Why?
| | Signal Transduction | 2 | 2020 | 4509 | 0.110 |
Why?
| | Smoking | 2 | 2018 | 1380 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 517 | 0.110 |
Why?
| | Risk Assessment | 5 | 2018 | 2967 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 757 | 0.110 |
Why?
| | Colorado | 4 | 2017 | 4099 | 0.110 |
Why?
| | Physicians | 1 | 2021 | 772 | 0.110 |
Why?
| | Nasopharynx | 2 | 2023 | 61 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 42 | 0.100 |
Why?
| | Prognosis | 4 | 2023 | 3328 | 0.100 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 159 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2311 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 336 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 80 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 671 | 0.100 |
Why?
| | Risk | 2 | 2012 | 812 | 0.100 |
Why?
| | Carbon Dioxide | 2 | 2023 | 218 | 0.100 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 26 | 0.100 |
Why?
| | Polysaccharides | 1 | 2012 | 78 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 452 | 0.100 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 22 | 0.100 |
Why?
| | Enoxaparin | 1 | 2012 | 52 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1008 | 0.100 |
Why?
| | Suction | 1 | 2011 | 31 | 0.100 |
Why?
| | Bacterial Load | 1 | 2011 | 58 | 0.100 |
Why?
| | Immunomodulation | 1 | 2012 | 84 | 0.100 |
Why?
| | Ultrasonography | 1 | 2015 | 633 | 0.090 |
Why?
| | Grief | 2 | 2021 | 35 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 284 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2017 | 1018 | 0.090 |
Why?
| | Anticoagulants | 2 | 2012 | 550 | 0.090 |
Why?
| | Pressure | 2 | 2023 | 214 | 0.090 |
Why?
| | Aged | 3 | 2024 | 19061 | 0.090 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 157 | 0.090 |
Why?
| | Interferons | 2 | 2022 | 151 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 225 | 0.090 |
Why?
| | Metagenome | 1 | 2011 | 122 | 0.090 |
Why?
| | RNA, Bacterial | 1 | 2011 | 174 | 0.090 |
Why?
| | Survival Rate | 3 | 2019 | 1644 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 234 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2279 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 197 | 0.090 |
Why?
| | Fetal Blood | 1 | 2012 | 270 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 1819 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1691 | 0.090 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 39 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 429 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2020 | 73 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.080 |
Why?
| | Influenza Vaccines | 1 | 2014 | 497 | 0.080 |
Why?
| | Survivors | 2 | 2022 | 411 | 0.080 |
Why?
| | Potassium | 2 | 2022 | 128 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 57 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4620 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2128 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 979 | 0.080 |
Why?
| | Hypoxia | 2 | 2024 | 957 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 63 | 0.070 |
Why?
| | Stroke Volume | 2 | 2021 | 504 | 0.070 |
Why?
| | Stem Cells | 1 | 2012 | 545 | 0.070 |
Why?
| | Purines | 1 | 2008 | 159 | 0.070 |
Why?
| | Transcriptome | 2 | 2023 | 725 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 115 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 923 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1211 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 174 | 0.070 |
Why?
| | Gene Expression | 2 | 2022 | 1421 | 0.070 |
Why?
| | Clinical Competence | 2 | 2023 | 893 | 0.070 |
Why?
| | Phenotype | 2 | 2023 | 2796 | 0.060 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 173 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 758 | 0.060 |
Why?
| | Cytokines | 1 | 2012 | 1840 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1021 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 42 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 35 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 5 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 534 | 0.060 |
Why?
| | Aorta | 2 | 2004 | 386 | 0.060 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 44 | 0.060 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 66 | 0.060 |
Why?
| | Disaccharides | 1 | 2023 | 16 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2023 | 27 | 0.060 |
Why?
| | Androstadienes | 1 | 2004 | 97 | 0.060 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 100 | 0.060 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 19 | 0.060 |
Why?
| | Corpus Callosum | 1 | 2023 | 56 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2023 | 39 | 0.060 |
Why?
| | Glycocalyx | 1 | 2023 | 18 | 0.060 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 26 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 33 | 0.050 |
Why?
| | Probability | 1 | 2004 | 289 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 102 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 159 | 0.050 |
Why?
| | Hyperoxia | 1 | 2004 | 99 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 107 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 140 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 337 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 1879 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 140 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 181 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 50 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 522 | 0.050 |
Why?
| | White Matter | 1 | 2023 | 104 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 565 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 40 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 254 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 48 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 329 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 398 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 399 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2218 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1727 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 201 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 385 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 358 | 0.050 |
Why?
| | Neonatologists | 1 | 2021 | 3 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 155 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 42 | 0.050 |
Why?
| | Influenza in Birds | 1 | 2020 | 3 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 750 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 75 | 0.040 |
Why?
| | Stromal Cells | 1 | 2020 | 96 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 72 | 0.040 |
Why?
| | Birds | 1 | 2020 | 76 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 41 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 935 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 16 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 68 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1569 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 311 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 236 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 28 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 499 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 41 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 127 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 719 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 143 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 76 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 385 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 138 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 188 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3003 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 102 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 340 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 497 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 186 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 264 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 944 | 0.040 |
Why?
| | Animals | 5 | 2020 | 31694 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 141 | 0.040 |
Why?
| | Rats | 2 | 2004 | 4958 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2024 | 479 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 237 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 442 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 262 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 785 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 329 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 537 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 243 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 287 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1372 | 0.040 |
Why?
| | Data Collection | 1 | 2020 | 620 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 425 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1518 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 69 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 248 | 0.040 |
Why?
| | Causality | 1 | 2017 | 103 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2020 | 436 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1104 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1342 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 187 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 739 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 136 | 0.030 |
Why?
| | Family | 1 | 2020 | 589 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 204 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 3881 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1767 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 338 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 547 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 768 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 532 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 106 | 0.030 |
Why?
| | Communication | 1 | 2021 | 744 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1448 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2552 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1139 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 908 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 868 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 645 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1317 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 35 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1796 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 176 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1889 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1124 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1133 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2477 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1214 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1466 | 0.020 |
Why?
| | Immune System | 1 | 2013 | 172 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1620 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 158 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 275 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 460 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 560 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 493 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2380 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1083 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 681 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 287 | 0.020 |
Why?
| | Mice | 1 | 2020 | 14860 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 26719 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 213 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 522 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3244 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|